Kintara Therapeutics Inc.
13F holders, Q2 2024 (June 30)17holders +4
7new positions
3sold out
$0.27avg. 13F price*
At the end of Q2 2024, 17 institutions reported holding Kintara Therapeutics Inc. in their 13F filings, up 4 from Q1 2024. 7 opened new positions and 3 sold out. The largest holders were Geode Capital Management, LLC ($93K), Susquehanna International Group, LLP ($30K) and UBS Group AG ($20K).
- Company
- Kintara Therapeutics Inc.
- CUSIP
- 49720K200
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $55K |
| Exits | 3 | $9K |
All 13F filers, Q1 2024 → Q2 2024: 522,511 shares bought and 199,167 shares sold, net +323,344 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Geode Capital Management, LLC | 0.00% | Add +696.8% | 343,912 | $93K |
| Susquehanna International Group, LLP | 0.00% | Add +8.4% | 109,255 | $30K |
| UBS Group AG | 0.00% | Reduce -45.3% | 75,822 | $20K |
| XTX Topco Ltd | 0.00% | New | 74,115 | $20K |
| Jane Street Group, LLC | 0.00% | Reduce -31.0% | 47,874 | $13K |
| Level Four Advisory Services, LLC | 0.00% | New | 44,642 | $12K |
| Baader Bank Aktiengesellschaft | 0.00% | New | 42,670 | $9K |
| Clear Creek Financial Management, LLC | 0.00% | New | 27,500 | $7K |
| Integrated Wealth Concepts LLC | 0.00% | New | 22,000 | $6K |
| Vanguard Group Inc. | 0.00% | No change | 12,455 | $3K |
| State Street Corp. | 0.00% | No change | 10,721 | $3K |
| Qube Research & Technologies Ltd | 0.00% | Reduce -59.1% | 2,700 | $729 |
| Bank of America Corp. | 0.00% | New | 2,268 | $612 |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -90.5% | 1,733 | $468 |
| Osaic Holdings, Inc. | 0.00% | Add +8.4% | 1,029 | $277 |
| FMR LLC | 0.00% | New | 20 | $5 |
| Acadian Asset Management LLC | 0.00% | No change | 350 | $0 |
"% of holder's portfolio" is KINTARA THERAPEUTICS INC's weight in each manager's 13F, not the share of Kintara Therapeutics Inc. the manager owns.